Comparative Pharmacology
Head-to-head clinical analysis: LIPIODOL versus RENOVUE DIP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPIODOL versus RENOVUE DIP.
LIPIODOL vs RENOVUE-DIP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lipiodol is an iodinated ethyl ester of the fatty acids of poppyseed oil. It acts as a radiopaque contrast agent for imaging due to its iodine content, and in chemoembolization, it selectively accumulates in hepatocellular carcinoma (HCC) via tumor neovasculature and is retained due to lack of lymphatic drainage, allowing targeted delivery of chemotherapeutic agents.
RENOVUE-DIP is a radiocontrast agent, not a drug with pharmacological activity. It is a diagnostic agent that contains diatrizoate meglumine and diatrizoate sodium, which are ionic iodinated compounds. They work by attenuating X-rays, providing contrast in imaging studies. The mechanism is physical rather than pharmacological, increasing the radiodensity of vascular structures and tissues.
Lymphangiography: 5-20 mL injected slowly into lymphatic vessels. Uterine/Fallopian tube imaging: 3-20 mL injected through cervix. Hepatic chemoembolization: 5-15 mL mixed with chemotherapeutic agents injected into hepatic artery.
5 mg orally once daily for hypertension; 2.5 mg orally once daily for diabetic nephropathy.
None Documented
None Documented
Terminal elimination half-life is approximately 50-60 days, reflecting slow clearance from lipid-rich tissues.
Terminal half-life: 2.5 hours (range 2–3 hours); clinically, dosing interval is every 4 hours due to slow redistribution from effect site.
Primarily eliminated via biliary/fecal route as unchanged drug; less than 1% excreted renally.
Renal: 95% (60% unchanged, 35% as major metabolite); Biliary/Fecal: 5% as conjugates.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent